BioSpace News Archive

Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced a grant of stock options to a new employee to purchase 6,520 shares of the Company’s common stock with an exercise price of $14.75 per share, the closing price of Assembly’s common stock on November 2, 2020. The stock optio

Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced financial results and recent corporate highlights for the third quarter ended September 30, 2020. “Mustang had an eventful third quarter on the regulatory front, as the U.S.

Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to two new employees consisting of 3,315 restricted stock units. The Compensation Committee of the Board of Directors approved the grants with an effective date of November 2, 2020. The restricted stock units were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The r

Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH) (“Spring Bank”), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology and inflammatory diseases, today announced that its board of directors intends, subject to the receipt of stockholder approval of the Exchange (as defined below) and the reverse stock split, to declare a one-time special dividend on each outstanding share of Spring Bank’s common stock, payable

PDL BioPharma, Inc. (“PDL” or “the Company”) (Nasdaq: PDLI) announces it has rescheduled the date for announcing third quarter 2020 financial results and holding a conference call to Wednesday, November 11 , 2020. PDL will issue

ProPhase Labs Inc. has acquired a New Jersey laboratory owned by Confucius Plaza Medical Laboratory. Kennedy Capital served as the exclusive brokerage to the transaction. The lab, which is approved for a variety of medical tests, including Covid-19 and respiratory pathogen panel molecular tests, will be owned by the company’

Conference call and webcast to take place on Wednesday, November 11, 2020 at 5:00 pm ET

Studies confirm improvement achieved and maintained through one year of active treatment with similar scores for patients switching from placebo to TREMFYA TREMFYA is the first and only U.S. FDA-approved selective anti-IL-23 therapy for active psoriatic arthritis and the only therapy for psoriatic arthritis to have improvement in fatigue as measured by FACIT-F in the product label

AVROBIO, Inc. announced that the company has granted non-statutory stock options for the purchase of up to an aggregate of 52,250 shares of the company’s common stock to four new employees as inducement awards under the company’s 2019 Inducement Plan, in accordance with Nasdaq Listing Rule 5635.

Third quarter 2020 revenue of $129 million Third quarter 2020 net loss of $42 million Third quarter 2020 Adjusted EBITDA 1 of $53 million Generated cash flow from operations of $113 million in the first nine months of 2020 Concluded the quarter with a cash and cash equivalents balance of $141 million